ArticleJournal of neurology2022
Time to onset and duration of botulinum toxin efficacy in movement disorders.
Article in Journal of neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 29 citations in OpenAlex.
- Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm - A Randomized Pilot Study.Translational vision science & technology · 2023Trial
- Comparison of Botulinum neurotoxin efficiency in dystonia associated with Parkinson's disease and atypical parkinsonism: a retrospective study with a self-reported improvement scale.Journal of neurology · 2022Trial
- Diaphragm-Directed Strategies for Prolonged Air Leak Prevention After Lung Resection: A Narrative Review of the Residual Pleural Space Paradigm.Journal of clinical medicine · 2026Review
- Prospective Study of Botulinum Toxin Effects on Nonmotor Symptoms and Quality of Life in Thai Patients With Craniocervical Dystonia.Journal of clinical neurology (Seoul, Korea) · 2026Article
- A belt-buckle checkpoint regulates the onset of botulinum neurotoxin intoxication.Nature communications · 2026Article
- Isolated bilateral temporalis hypertrophy: a rare case report and technical insight into botulinum toxin type A injection.Journal of the Korean Association of Oral and Maxillofacial Surgeons · 2025Article
- Botulinum toxin as a potential adjunct therapy in stiff person syndrome spectrum disorders.Therapeutic advances in neurological disorders · 2025Article
- Dosage of botulinum toxin in patients undergoing treatment for hemifacial spasm: is there modification during follow-up?Arquivos de neuro-psiquiatria · 2025Article
- A Six-Year Examination of the Influence of Surgical Technique and Intraoperative Intraglandular Clostridium Botulinum Toxin Application in Salivary Gland Tumor Operations.Journal of clinical medicine · 2024Article
- Review
- Article
- Decompression Surgery in Elderly Patients with Hemifacial Spasm Refractory to Botulinum Toxin.Movement disorders clinical practice · 2024Article
- Article
- Crocodile tear syndrome treated with lacrimal gland incobotulinum toxin A injection: a report of two cases.Digital journal of ophthalmology : DJO · 2023Article
- Lasting Peripheral and Central Effects of Botulinum Toxin Type A on Experimental Muscle Hypertonia in Rats.International journal of molecular sciences · 2022Article
- Experiences of patients with poststroke spasticity throughout a botulinum toxin treatment cycle: Results from a prospective ethnographic study.Frontiers in neurology · 2022Article
- Development and validation of a nomogram for predicting recurrence in patients with Meige syndrome after radiofrequency ablation.Frontiers in neurologyArticle
- A combined therapeutic approach: extracorporeal shock wave therapy and botulinum toxin in multiple sclerosis-related spasticity.Frontiers in neurologyArticle
- Intervention effects of different brands of botulinum toxin type A on Meige syndrome with anxiety symptoms.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBotulinum toxin (BoNT) is a valuable treatment in movement disorders; however, time to onset and duration of efficacy may widely differ among patients. We aimed to clarify the impact of main demographic and clinical features on time to onset and duration of BoNT efficacy.
methodsWe analyzed time-to-onset and duration of BoNT efficacy in 186 consecutive patients treated with BoNT for blepharospasm, cervical dystonia, facial hemispasm, oromandibular dystonia, limb dystonia, and sialorrhea due to Parkinsonism. The following factors were considered as potential efficacy predictors: doses and types of toxin, sex, age, years of treatment, and clinical condition. Kruskall-Wallis, Spearman correlation, and multivariate linear regression were used for statistical analysis.
resultsThe average time to onset was 6.7 ± 5 days and duration of BONT efficacy 78.5 ± 28.4 days. Both time to onset and duration of efficacy were correlated with BoNT doses (p: 0.007 and p: 0.02). The multiple regression analysis showed that sex, age, years of BoNT treatment, doses, type of toxin, and clinical condition significantly predicted time to onset (F(11, 171) = 2.146, p: 0.020) with age being the strongest predictor (p: 0.004). The same model explained 20.1% of the variance of duration of BoNT efficacy, showing a significant prediction of the outcome (F(11, 164) = 3.754, p < 0.001), with doses (p < 0.001), type of toxin (p: 0.017), and clinical condition (p < 0.001) being the strongest predictors.
conclusionOur findings suggest that age, type of toxin, clinical condition and especially doses may account for the variability of BoNT efficacy in terms of time to onset and duration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.